From: Systematic review of health state utility values for economic evaluation of colorectal cancer
Reference | Valuation methods used | HSUVs |
---|---|---|
Bennett [56] | EQ-5D | 1st line Panitimumab + FOLFOX4 0.778; FOLFOX4 0.756 2nd line Panitimumab + FOLFIRI 0.769; FOLFIRI 0.762 |
Best [4] | TTO | CRC patients/community members Remission 0.83/0.82 adjuvant, no neuropathy 0.61/0.60 adjuvant, mild neuropathy 0.61/0.51 adjuvant, moderate neuropathy 0.53/0.46 adjuvant, severe neuropathy 0.48/0.34 metastatic, stable 0.40)/0.51 metastatic, progressive 0.37/0.21 |
Dranitsaris [48]b | TTO | FOLFOX + ‘new drug’ → FOLFIRI → BSC until death [2–33 months] 0.68-0.89 FOLFOX → FOLFIRI → BSC until death [2–32 months] 0.70-0.94 |
Dranitsaris [36]b | TTO | FOLFOX±’new drug’ → FOLFIRI → BSC until death [2–29 months] 0.67-0.83 FOLFOX → FOLFIRI → BSC until death [2–32 months] 0.72-0.91 |
Dranitsaris [48]b | TTO | FOLFOX + ‘new drug’ → FOLFIRI → BSC until death [2–29 months] 0.52-0.84 FOLFOX → FOLFIRI → BSC until death [2–32 months] 0.53-0.84 |
Dranitsaris [36]b | TTO | FOLFOX + ‘new drug’ → FOLFIRI → BSC until death [2–28 months] 0.44-0.72 FOLFOX → FOLFIRI → BSC until death [2–32 months] 0.44-0.71 |
Farkkila [51] | EQ-5D | Metastatic disease 0.820 Palliative care 0.643 |
Mittmann [38]b | HUI3 | Cetuximab + BSC 0.71-0.77 BSC 0.66-0.71 |
Odom [58] | EQ-5D | Panitumumab plus BSC; BSC alone Overall 0.72; 0.68 Wild-type KRAS 0.73; 0.68 Mutant KRAS 0.71; 0.68 |
Petrou [20]a | SG | Partial response 1.0 Stable disease 0.95 Progressive disease 0.575 Terminal disease 0.1 |
Shiroiwa [44] | TTO | XELOX without AEs 0.59 FOLFOX without AEs 0.53 Febrile neutropenia 0.39 Nausea/vomiting 0.38 Diarrhoea 0.42 Hand-foot syndrome 0.39 Fatigue 0.45 Peripheral neuropathy 0.45 Stomatitis 0.42 |
Wang [60] | EQ-5D | Panitumumab + BSC; BSC TOX 0.6008; 0.4409 TWiST 0.7678; 0.6630 REL 0.6318; 0.6407 |
Wiering [29] | EQ-5D | Disease-free 0.78 non-curative 0.67 recurrence 0.74 recurrence with chemotherapy 0.82 Recurrent without chemotherapy 0.68 |
Ward [14] | EQ-VAS | Capecitabine and bevacizumab Baseline 61.76 (SD 23.15) Cycle 2 68.59 (SD 22.26) [p = 0.06] End of study 66.54 (SD 23.18) [p = 0.29] |